Vitamica

Vitamica, established in early 2018 as a spin-out from the University of Bristol, leverages advanced optical technology to offer a novel diagnostic method for rapid antimicrobial susceptibility testing. This technology is designed to quickly differentiate between antibiotic-resistant and susceptible cells, addressing a critical need in the healthcare, veterinary, and pharmaceutical markets. The company primarily serves healthcare providers, veterinary clinics, and pharmaceutical companies, aiming to improve the speed and accuracy of diagnosing infections and determining appropriate treatments. Vitamica operates in the diagnostic technology market, focusing on antimicrobial resistance (AMR) solutions. Its business model revolves around commercializing its proprietary technology through product sales and potential licensing agreements. Revenue is generated from the sale of diagnostic devices and related services. The company benefits from a strong intellectual property (IP) portfolio and an active approach to identifying new opportunities in its target sectors. Supported by a Scientific Advisory Panel of experienced clinical and academic microbiologists, Vitamica is well-positioned to make significant advancements in the field of rapid diagnostics.

Keywords: antimicrobial resistance, optical technology, rapid diagnostics, healthcare, veterinary, pharmaceutical, infection testing, IP portfolio, microbiology, commercialization.